🌍 Obesity, Orals, Outcomes: Rewriting the GLP-1 Script

💊 Orforglipron: A new era in obesity treatment?   In the ATTAIN-1 trial, this oral, nonpeptide GLP-1 receptor agonist delivered up to 11.2% weight loss over 72 weeks—with significant drops in waist circumference, triglycerides, and blood pressure 📉🌡️   🔥 Nearly 1 in 5 patients lost ≥20% body weight 💡 A promising alternative to injectable therapies   Accessible. Effective. Oral. 👉 A game-changer for global obesity care?   #Obesity #GLP1 #Orforglipron #WeightLoss #CardiometabolicHealth #NEJM #Innovation #ClinicalTrials #Endocrinology #PublicHealth #Pharmacotherapy